Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S
Nordicus Partners (OTCQB: NORD) has announced the acquisition of the remaining 5% shares in Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company focused on periodontitis treatment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nordicus Partners (OTCQB: NORD) has announced the acquisition of the remaining 5% shares in Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company focused on periodontitis treatment. The transaction involves 200,000 restricted common shares of Nordicus in exchange for the outstanding Orocidin shares, making Orocidin a 100% wholly-owned subsidiary of Nordicus. The deal strengthens Nordicus's position in facilitating Nordic and U.S. life sciences companies' establishment in the U.S. market.
Positive
- Complete ownership (100%) acquired of Orocidin A/S, strengthening corporate control
- All-stock transaction preserves cash resources
Negative
- Share dilution due to issuance of 200,000 new restricted common shares
Details
News Market Reaction – NORD
The recorded move for NORD in the trading session of this news was -59.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Beverly Hills, California., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire the remaining approximately
Upon closing of the acquisition, Orocidin became a
About Orocidin A/S
Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company, is aiming to revolutionize the treatment of aggressive periodontitis, making it safer, more effective, and efficient to prevent and cure those who are affected by periodontitis. For more information about Orocidin, please visit: www.orocidin.com
About Nordicus Partners Corporation
Nordicus Partners Corporation specializes in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and U.S. companies in different areas of corporate finance activities, such as: business- and market development, growth strategies, attracting the right people, partners and capital for businesses and company acquisitions and sales. In May 2024 Nordicus bought
Forward-Looking Statements
The Company believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of these terms) may identify forward-looking statements. Such forward-looking statements, including but not limited to statements regarding the plans and objectives of management for future operations, are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the accuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, market acceptance of the company’s products and services; competition from existing products or new products that may emerge; the implementation of the company’s business model and strategic plans for its business and our products; estimates of the company’s future revenue, expenses, capital requirements and need for financing; current and future government regulations; and developments relating to the company’s competitors. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.
For further information contact
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email hr@nordicuspartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.